Abstract
The inexorable process of aging is characterised by the systemic decline of cellular function, tissue integrity, and regenerative capacity, culminating in increased susceptibility to chronic disease and frailty. While chronological aging is immutable, the biological aging process has become a target for therapeutic intervention. Among the most promising frontiers in gero-science is stem cell-based rejuvenation. This paradigm aims not only to mitigate symptoms but also to restore youthful function at both cellular and systemic levels. This review synthesises the current state of research on stem cell therapies for anti-aging, focusing on their mechanistic potential to enhance tissue repair, modulate inflammation, and reverse epigenetic aging signatures. It critically examines the principal modalities, including mesenchymal stem cell (MSC) transplantation, induced pluripotent stem cell (iPSC) derivatives, and endogenous stem cell niche rejuvenation. However, the translation of this promise into clinical reality is fraught with significant challenges, including tumorigenic risk, immune rejection, cellular senescence of therapeutic cells, high costs, and a lack of standardised regulatory frameworks. Furthermore, ethical considerations surrounding source materials and the prevention of biological age disparity complicate the landscape. We conclude that while stem cell-based regenerative strategies hold revolutionary potential for extending human healthspan, their success hinges upon overcoming these multifaceted scientific, clinical, and ethical hurdles through rigorous research, robust clinical trials, and thoughtful policy development.